telavancin (Rx)

Brand and Other Names:Vibativ
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection, lyophylized powder

  • 750mg/vial

Skin & Skin Structure Infections

Indicated for skin and skin structure infections caused by Gram-positive bacteria including Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (includes S anginosus, S intermedius, and S constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only)

10 mg/kg IV q24hr for 7-14 days; infuse over 1 hr  

Pneumonia

Indicated for hospital-acquired, including ventilator-associated bacterial pneumonia caused by susceptible isolates of Staphylococcus aureus (including methacillin-relesistant and vancomycin-intermediate strains) when alternative treatments are not suitable

10 mg/kg IV q24hr for 7-21 days; infuse over 1 hr  

Dosage Modifications

Renal impairment

  • CrCl 30-50 mL/minute: 7.5 mg/kg IV q24hr
  • CrCl 10-29 mL/minute: 10 mg/kg IV q48hr

Dosing Considerations

Pneumonia: Approved only to treat Staphylococcus aureus, not other pneumonia-causing bacteria

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and telavancin

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (31)

              • amiodarone

                amiodarone and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

              • arsenic trioxide

                arsenic trioxide and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

              • artemether

                artemether and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

              • ceritinib

                ceritinib and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

              • cholera vaccine

                telavancin, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.

              • disopyramide

                disopyramide and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

              • entrectinib

                telavancin and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.

              • eribulin

                eribulin and telavancin both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.

              • fexinidazole

                fexinidazole and telavancin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.

              • glasdegib

                telavancin and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.

              • hydroxychloroquine sulfate

                hydroxychloroquine sulfate and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

              • ibutilide

                ibutilide and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

              • indapamide

                indapamide and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

              • inotuzumab

                inotuzumab and telavancin both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.

              • ivosidenib

                ivosidenib and telavancin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.

              • lefamulin

                lefamulin and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

              • macimorelin

                macimorelin and telavancin both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.

              • ondansetron

                ondansetron and telavancin both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.

              • panobinostat

                telavancin and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.

              • pentamidine

                pentamidine and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

              • pimozide

                pimozide and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

              • pitolisant

                telavancin and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.

              • procainamide

                procainamide and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

              • quinidine

                quinidine and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

              • ribociclib

                ribociclib increases toxicity of telavancin by QTc interval. Avoid or Use Alternate Drug.

              • saquinavir

                saquinavir, telavancin. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug.

              • sotalol

                sotalol and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

              • umeclidinium bromide/vilanterol inhaled

                telavancin increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.

              • vandetanib

                telavancin, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.

              • vemurafenib

                vemurafenib and telavancin both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.

              • vilanterol/fluticasone furoate inhaled

                telavancin increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.

              Monitor Closely (98)

              • albuterol

                albuterol and telavancin both increase QTc interval. Use Caution/Monitor.

              • alfuzosin

                telavancin and alfuzosin both increase QTc interval. Use Caution/Monitor.

                alfuzosin and telavancin both increase QTc interval. Use Caution/Monitor.

              • amitriptyline

                amitriptyline and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • amoxapine

                amoxapine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • apomorphine

                apomorphine and telavancin both increase QTc interval. Use Caution/Monitor.

              • arformoterol

                arformoterol and telavancin both increase QTc interval. Use Caution/Monitor.

              • aripiprazole

                aripiprazole and telavancin both increase QTc interval. Use Caution/Monitor.

              • artemether/lumefantrine

                artemether/lumefantrine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • atomoxetine

                atomoxetine and telavancin both increase QTc interval. Use Caution/Monitor.

              • bedaquiline

                telavancin and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely

              • chlorpromazine

                chlorpromazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • ciprofloxacin

                ciprofloxacin and telavancin both increase QTc interval. Use Caution/Monitor. Ciprofloxacin elicits minimal effects on QT interval. Caution if used in combination with other drugs known to affect QT interval or in patients with other risk factors.

              • citalopram

                telavancin and citalopram both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.

              • clarithromycin

                clarithromycin and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • clomipramine

                clomipramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • crizotinib

                crizotinib and telavancin both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.

              • dasatinib

                dasatinib and telavancin both increase QTc interval. Use Caution/Monitor.

              • desipramine

                desipramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • dofetilide

                dofetilide and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • dolasetron

                dolasetron and telavancin both increase QTc interval. Use Caution/Monitor.

              • doxepin

                doxepin and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • dronedarone

                dronedarone and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • droperidol

                droperidol and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • epinephrine

                epinephrine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • epinephrine racemic

                epinephrine racemic and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • erythromycin base

                erythromycin base and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • erythromycin ethylsuccinate

                erythromycin ethylsuccinate and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • erythromycin lactobionate

                erythromycin lactobionate and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • erythromycin stearate

                erythromycin stearate and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • escitalopram

                escitalopram increases toxicity of telavancin by QTc interval. Use Caution/Monitor.

              • ezogabine

                ezogabine, telavancin. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.

              • flecainide

                flecainide and telavancin both increase QTc interval. Use Caution/Monitor.

              • fluconazole

                fluconazole and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • fluoxetine

                fluoxetine and telavancin both increase QTc interval. Use Caution/Monitor.

              • fluphenazine

                fluphenazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • fluvoxamine

                fluvoxamine and telavancin both increase QTc interval. Use Caution/Monitor.

              • formoterol

                formoterol and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • foscarnet

                foscarnet and telavancin both increase QTc interval. Use Caution/Monitor.

              • fostemsavir

                telavancin and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.

              • gemtuzumab

                telavancin and gemtuzumab both increase QTc interval. Use Caution/Monitor.

              • goserelin

                goserelin increases toxicity of telavancin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • haloperidol

                haloperidol and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • histrelin

                histrelin increases toxicity of telavancin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • iloperidone

                iloperidone and telavancin both increase QTc interval. Use Caution/Monitor.

              • imipramine

                imipramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • indacaterol, inhaled

                indacaterol, inhaled, telavancin. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.

              • ketoconazole

                ketoconazole and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • lapatinib

                lapatinib and telavancin both increase QTc interval. Use Caution/Monitor.

              • lenvatinib

                telavancin and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.

              • leuprolide

                leuprolide increases toxicity of telavancin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • levofloxacin

                levofloxacin and telavancin both increase QTc interval. Use Caution/Monitor.

              • lofepramine

                lofepramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • lumefantrine

                lumefantrine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • maprotiline

                maprotiline and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • methadone

                methadone and telavancin both increase QTc interval. Use Caution/Monitor.

              • mifepristone

                mifepristone, telavancin. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.

              • moxifloxacin

                moxifloxacin and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • nilotinib

                nilotinib and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • nortriptyline

                nortriptyline and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • octreotide

                octreotide and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • octreotide (Antidote)

                octreotide (Antidote) and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • ofloxacin

                ofloxacin and telavancin both increase QTc interval. Use Caution/Monitor.

              • olodaterol inhaled

                telavancin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias

              • osilodrostat

                osilodrostat and telavancin both increase QTc interval. Use Caution/Monitor.

              • osimertinib

                osimertinib and telavancin both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.

              • oxaliplatin

                oxaliplatin will increase the level or effect of telavancin by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.

              • ozanimod

                ozanimod and telavancin both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.

              • paliperidone

                paliperidone and telavancin both increase QTc interval. Use Caution/Monitor.

              • paroxetine

                paroxetine and telavancin both increase QTc interval. Use Caution/Monitor.

              • pasireotide

                telavancin and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.

              • perphenazine

                perphenazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • posaconazole

                posaconazole and telavancin both increase QTc interval. Use Caution/Monitor.

              • prochlorperazine

                prochlorperazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • promazine

                promazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • promethazine

                promethazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • protriptyline

                protriptyline and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • quetiapine

                quetiapine, telavancin. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.

              • quinine

                telavancin and quinine both increase QTc interval. Use Caution/Monitor.

              • ranolazine

                ranolazine and telavancin both increase QTc interval. Use Caution/Monitor.

              • rilpivirine

                rilpivirine increases toxicity of telavancin by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsade de Pointes.

              • risperidone

                risperidone and telavancin both increase QTc interval. Use Caution/Monitor.

              • romidepsin

                romidepsin and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • selpercatinib

                selpercatinib increases toxicity of telavancin by QTc interval. Use Caution/Monitor.

              • sodium picosulfate/magnesium oxide/anhydrous citric acid

                telavancin decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.

              • sorafenib

                sorafenib and telavancin both increase QTc interval. Use Caution/Monitor.

              • sulfamethoxazole

                sulfamethoxazole and telavancin both increase QTc interval. Use Caution/Monitor.

              • tenofovir DF

                telavancin, tenofovir DF. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

                telavancin increases levels of tenofovir DF by decreasing renal clearance. Use Caution/Monitor.

              • thioridazine

                thioridazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • trazodone

                trazodone and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • trifluoperazine

                trifluoperazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • trimethoprim

                telavancin and trimethoprim both increase QTc interval. Use Caution/Monitor.

              • trimipramine

                trimipramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • triptorelin

                triptorelin increases toxicity of telavancin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • tropisetron

                telavancin and tropisetron both increase QTc interval. Use Caution/Monitor.

              • venlafaxine

                telavancin and venlafaxine both increase QTc interval. Use Caution/Monitor.

              • voclosporin

                voclosporin, telavancin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

              • voriconazole

                telavancin and voriconazole both increase QTc interval. Use Caution/Monitor.

              • ziprasidone

                telavancin and ziprasidone both increase QTc interval. Modify Therapy/Monitor Closely.

              Minor (4)

              • azithromycin

                azithromycin and telavancin both increase QTc interval. Minor/Significance Unknown.

              • chloroquine

                chloroquine increases toxicity of telavancin by QTc interval. Minor/Significance Unknown.

              • entecavir

                telavancin, entecavir. Either increases effects of the other by decreasing renal clearance. Minor/Significance Unknown. Coadministration with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.

              • pazopanib

                pazopanib and telavancin both increase QTc interval. Minor/Significance Unknown.

              Previous
              Next:

              Adverse Effects

              >10%

              Taste disturbance

              Nausea

              Vomiting

              Foamy urine

              1-10%

              Diarrhea

              Dizziness

              Rigors

              Pruritus

              Rash

              Previous
              Next:

              Warnings

              Black Box Warnings

              Renal impairment

              • Increased mortality compared with vancomycin in patients with pre-existing moderate/severe renal impairment (CrCl 50 mL/min or less) who were treated for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia
              • Use with pre-existing moderate/severe renal impairment should be considered only when the anticipated benefit to the patient outweighs the potential risk
              • Nephrotoxicity: New onset or worsening renal impairment has occurred; monitor renal function in all patients

              Pregnancy

              • Women of childbearing potential should have a serum pregnancy test prior to administration
              • Avoid during pregnancy unless potential benefit to the patient outweighs potential risk to the fetus
              • Adverse developmental outcomes observed in 3 animal species at clinically relevant doses raise concerns about potential adverse developmental outcomes in humans

              Contraindications

              Hypersensitivity

              Use of intravenous unfractionated heparin sodium

              Cautions

              New onset or worsening renal impairment has been reported (monitor renal function)

              Efficacy decreased with moderate-to-severe baseline renal impairment (ie, CrCl <50 mL/min) for skin and skin structure infections

              Administer over at least 1 hr to minimize infusion-related adverse reactions

              Clostridium difficile-associated diarrhea may occur

              May prolong QTc interval; coadministration with other drugs that prolong QTc interval (eg, phenothiazine, TCAs, macrolide antibiotics, class I and III antiarrhythmic agents) increased risk for life-threatening arrhythmias

              Interferes with coagulation tests including PT, INR, and APT, but does not interfere with coagulation

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy

              There is a pregnancy registry that monitors pregnancy outcomes in women exposed to therapy during pregnancy; physicians are encouraged to register pregnant patients, or pregnant women may enroll themselves in the VIBATIV pregnancy registry by calling 1-877-484-2700

              There are no available data on therapy use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; based on findings in animal reproduction studies, drug may cause fetal harm; advise pregnant women of potential risk to fetus; estimated background risk of major birth defects and miscarriage for indicated population is unknown

              In embryo-fetal development studies in rats, rabbits, and minipigs, telavancin demonstrated potential to cause limb and skeletal malformations when given intravenously during the period of organogenesis at doses providing approximately 1- to 2-fold the human exposure at maximum recommended clinical dose

              Verify pregnancy status in females of reproductive potential prior to initiating therapy

              Contraception

              • Females:Therapy may cause fetal harm when administered to a pregnant woman; advise females of reproductive potential to use effective contraception during treatment and for 2 days after final dose

              Infertility

              • Males: Based on findings in rats, therapy may impair male fertility; effect on fertility was reversible in rats

              Lactation

              There are no data on presence of telavancin in human milk, effects on breastfed child, or on milk production; developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal conditions

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Lipoglycopeptide antibiotic that is a synthetic derivative of vancomycin

              Inhibits bacterial cell wall synthesis by interfering with polymerization and cross-linking of peptidoglycan

              Unlike vancomycin, telavancin also depolarizes the bacterial cell membrane and disrupts its functional integrity

              Absorption

              Poor oral absorption

              Distribution

              Protein Bound: 90%

              Vd: 133-145 mL/kg

              Metabolism

              Metabolic pathway not yet identified; not metabolized by CYP450 isoenzymes

              Elimination

              Half-life: 8 hr

              Clearance: 13.1-13.9 mL/hr/kg

              Excretion: 75% urine; <1% feces

              Previous
              Next:

              Administration

              IV Compatibility

              Data limited

              Do not add other drugs or infuse simultaneously through same IV line

              Flush IV line before and after infusion for sequential infusion of additional medications

              IV Preparation

              750 mg vial reconstitution

              • Reconstitute lyophilized powder by adding 45 mL of D5W, SWI, or 0.9% NaCl
              • Resultant solution concentration 15 mg/mL (total volume ~50 mL)

              Further dilution

              • Solutions for further dilution before infusion include: D5W, 0.9% NaCl, lactated Ringer's injection
              • Doses of 150-800 mg: dilute further in 100-250 mL of IV solution
              • Doses <150 mg or >800 mg: dilute further to final concentration of 0.6-8 mg/mL

              IV Administration

              Intermittent IV infusion over 60 min

              Storage

              No preservative or bacteriostatic agent in product

              Unopened vials

              • Refrigerate at 2-8°C (35-46°F); excursions to ambient temperatures (up to 25°C [77°F]) are acceptable
              • Avoid excessive heat

              Reconstituted solution or further diluted

              • Stored at room temperature: Use within 4 hr
              • Stored refrigerated: Use within 72 hr
              Previous
              Next:

              Images

              BRAND FORM. UNIT PRICE PILL IMAGE
              Vibativ intravenous
              -
              750 mg vial

              Copyright © 2010 First DataBank, Inc.

              Previous
              Next:

              Patient Handout

              Patient Education
              telavancin intravenous

              TELAVANCIN - INJECTION

              (TEL-a-VAN-sin)

              COMMON BRAND NAME(S): Vibativ

              WARNING: Adults with moderate to severe kidney disease who are using telavancin to treat serious lung infections may be at an increased risk for death. Discuss the risks and benefits of this medication, as well as other effective and possibly safer treatments for lung infections, with your doctor.Telavancin may cause or worsen kidney problems. Problems are more likely to occur if you have heart failure, kidney disease, diabetes, or high blood pressure, or if you take certain medications (see also Drug Interactions section). Kidney function tests must be performed before you start treatment, during treatment, and after you finish treatment to check for kidney problems. Tell your doctor right away if you have any signs of kidney problems such as a change in the amount of urine.Tell your doctor if you are pregnant or plan to become pregnant. Your doctor may order a pregnancy test before starting this medication. You should not become pregnant while using telavancin. Telavancin may harm an unborn baby. Women of childbearing age should ask about reliable forms of birth control while using this medication and for 2 days after the last dose. If you become pregnant, talk to your doctor right away about the risks and benefits of this medication.

              USES: This medication is an antibiotic used to treat serious bacterial infections of the skin and certain types of pneumonia. It works by stopping the growth of bacteria.

              HOW TO USE: Read the Medication Guide provided by your pharmacist before you start using telavancin and each time you get a refill. If you have any questions, ask your doctor or pharmacist.This medication is given by injection into a vein as directed by your doctor, usually once a day. It should be injected slowly over 60 minutes. The dosage and length of treatment is based on your weight, medical condition, and response to treatment.If you are giving this medication to yourself at home, learn all preparation and usage instructions from your health care professional. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Learn how to store and discard medical supplies safely.For the best effect, use this antibiotic at evenly spaced times. To help you remember, use this medication at the same time(s) every day.Continue to use this medication until the full prescribed amount is finished, even if symptoms disappear after a few days. Stopping the medication too early may allow bacteria to continue to grow, which may result in a return of the infection.Tell your doctor if your condition persists or worsens.

              SIDE EFFECTS: See also Warning section.Flushing of the upper body may occur if this medication is injected too fast ("red man syndrome"). Tell your doctor right away if this occurs. The infusion of this medication may need to be slowed or stopped.Metallic/soapy taste, nausea, vomiting, or foamy urine may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Get medical help right away if any of these rare but serious side effects occur: fast/irregular heartbeat, severe dizziness, fainting.This medication may rarely cause a severe intestinal condition due to a bacteria called C. difficile. This condition may occur during treatment or weeks to months after treatment has stopped. Tell your doctor right away if you develop: diarrhea that doesn't stop, abdominal or stomach pain/cramping, blood/mucus in your stool.If you have these symptoms, do not use anti-diarrhea or opioid products because they may make symptoms worse.Use of this medication for prolonged or repeated periods may result in oral thrush or a new vaginal yeast infection. Contact your doctor if you notice white patches in your mouth, a change in vaginal discharge, or other new symptoms.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any of the following symptoms of a serious allergic reaction: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

              PRECAUTIONS: See also Warning section.Before using telavancin, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history.Telavancin may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can rarely cause serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that need medical attention right away.The risk of QT prolongation may be increased if you have certain medical conditions or are taking other drugs that may cause QT prolongation. Before using telavancin, tell your doctor or pharmacist of all the drugs you take and if you have any of the following conditions: certain heart problems (heart failure, slow heartbeat, QT prolongation in the EKG), family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).Low levels of potassium or magnesium in the blood may also increase your risk of QT prolongation. This risk may increase if you use certain drugs (such as diuretics/"water pills") or if you have conditions such as severe sweating, diarrhea, or vomiting. Talk to your doctor about using telavancin safely.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Telavancin may cause live bacterial vaccines (such as typhoid vaccine) to not work as well. Do not have any immunizations/vaccinations while using this medication unless your doctor tells you to.Older adults may be more sensitive to the side effects of this drug, especially QT prolongation (see above).During pregnancy, this medication should be used only when clearly needed. It may harm an unborn baby. Consult your doctor for more details. (See also Warning section.)It is unknown if this medication passes into breast milk. Consult your doctor before breast-feeding.

              DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: other drugs that may affect the kidneys (including NSAIDs such as ibuprofen), "blood thinners" (such as heparin).This medication may interfere with certain laboratory tests (including coagulation tests such as PT/INR/APPT, urine protein tests), possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this drug.

              OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

              NOTES: See also Warning section.Laboratory and/or medical tests (such as kidney function) may be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.

              MISSED DOSE: It is important to get each dose of this medication as scheduled. If you miss a dose, ask your doctor or pharmacist right away for a new dosing schedule. Do not double the dose to catch up.

              STORAGE: Consult the product instructions and your pharmacist for storage details. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

              Information last revised August 2021. Copyright(c) 2021 First Databank, Inc.

              IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.